ImmunityBio, Inc.IBRX

ImmunityBio’s latest quarterly filing reads less like a balance sheet and more like a thermometer in a hurricane: $44.2 million in revenue, yes, but a net loss of $632.8 million and a balance sheet that has tipped from red to deeply redder, with liabilities of $1.52 billion and shareholders’ equity of minus $870 million. That’s not a company with a cash problem; it’s a company that has turned the dial past red into a full-scale haemorrhage. The cash position, at $205.2 million, looks healthy until you remember it’s haemorrhaging $75.4 million a quarter in operating cash. The filings don’t just show red ink; they show a company trying to sell a living-cell therapy while its ledger is haemorrhaging faster than a haemophiliac at a knife fight.

ImmunityBio sells ANKTIVA, a cell therapy approved by the FDA in April 2024, and its revenue is generated from U.S. sales of that single product. The company’s press releases trumpet ‘sales momentum’-preliminary net product revenue of $113 million in a later release-but the SEC filings tell the quieter story: $44.2 million in reported revenue for the quarter to March 31, 2026, alongside a $632.8 million net loss and a balance sheet with liabilities of $1.52 billion against $646.6 million in assets. The gap between the platform story and the filings is not a tone issue; it is a structural mismatch between aspiration and arithmetic.

The company’s operating loss for the quarter was $69.8 million, and it burned $75.4 million in operating cash. Cash and equivalents stood at $205.2 million, while inventory rose by $5 million to $547,000-numbers that do not suggest a company scaling up production, but one testing the limits of its runway. Diluted EPS was negative $0.62 on 1.03 billion shares, and the company’s related-party transactions included $1.2 million for clinical trial and transition services, which reads like the left hand billing the right hand for holding the patient’s hand. The board’s latest Form 4s do not disclose share-price details, only boilerplate about providing information upon request, which is corporate-speak for ‘ask the SEC if you want to know who sold what and at what price.’

The company’s investor materials point to ‘nearly 2.7 times year-over-year revenue growth’ and ‘$381 million in cash and marketable securities,’ but the 10-Q for the quarter ending March 31, 2026 shows a different reality: $44.2 million in revenue, $632.8 million in net loss, and a balance sheet that is technically insolvent in shareholders’ equity terms. The ‘preliminary’ $113 million revenue figure for a later period is not in the filed 10-Q and has not been audited or reconciled in a public filing. The company’s website and press releases can spin momentum; the filings are the ones that count.

The company’s cash haemorrhage accelerated to $75.4 million in operating outflows for the quarter, while cash and equivalents fell to $205.2 million. The filings do not provide segment-level detail, forward guidance, or a clear path to profitability. The company’s single FDA-approved product, ANKTIVA, is the sole revenue engine, and its sales trajectory is the only concrete data point in a sea of red ink. The company has not provided a segment breakdown, capex guidance, or a clear inventory turnover metric in the latest filings, leaving investors to guess how much cash is tied up in product versus how much is haemorrhaging out the door. The company’s investor relations page and news rail describe ‘innovative treatments from living technologies’ and ‘global health enhancement,’ but the filings are the ones that record the haemorrhage.